Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor.

This article discusses a study on double expressor lymphoma (DEL) subtypes and the therapeutic mechanism of epigenetic agents. The study identified three subtypes of DEL with unique characteristics and found that DEL had an inferior survival compared to double negative lymphoma (DNL). The subtypes of DEL were associated with different cell-of-origin and genetic classifications. The study also analyzed the effects of tucidinostat and doxorubicin treatment on different oncogenic transcriptional factors and signaling networks in these subtypes. The results showed distinct molecular heterogeneity and a complex tumor microenvironment in DEL, which contribute to resistance to standard treatment. However, tucidinostat plus doxorubicin demonstrated broad-spectrum sensitivity in vitro and in vivo. The study provides insights for optimizing current treatment paradigms in DEL. [Extracted from the article]